Discoverpodcast – Clinical CorrelationsCore IM: Mind the Gap on Vancomycin
Core IM: Mind the Gap on Vancomycin

Core IM: Mind the Gap on Vancomycin

Update: 2018-08-01
Share

Description

In this episode, we discuss the misunderstood side of our antibiotic hero, Vancomycin || By Steven R. Liu MD, John Hwang MD and Dr. Janine Knudsen MD || Graphic Design by Ramon Thompson

Time Stamps:



*     Where did vancomycin come from, and why is it so controversial? (0:28 )

*     What is vancomycin-induced nephrotoxicity and how common is it? (4:37 )

*     Vancomycin trough monitoring – what is it good for?  (7:28 )

*     AUC to MIC ratio – the real math behind vancomycin dosing (7:53 )

*     Review of teaching points (10:27 )



Thank you to ID pharmacists from NYU, Polly Shin-Pung Jen, PharmD and Justin Siegfried, PharmD, for peer reviewing this podcast!

Subscribe to CORE IM on any podcast app! Follow us on Facebook @Core IM || Twitter @COREIMpodcast || Instagram @core.im.podcast. Please give any feedback at COREIMpodcast@gmail.com.



Show Notes:



* Initial formulations of vancomycin were only 70% pure, giving it its original muddy brown color.  Side effects seen included cytopenias, “red man syndrome”, and nephrotoxicity. With better technology, vancomycin is now 95% pure, and as a result has fewer side effects.

* Vancomycin nephrotoxicity is defined by the IDSA as an increase in creatinine of 0.5mg/dL or by more than 50%, whichever is bigger.

* Vancomycin causes nephrotoxicity through two mechanisms: acute interstitial nephritis (an allergic reactions) or renal tubular damage from oxidative stress.

* Rates of nephrotoxicity appear to be low, although the exact number is difficult to determine. Most studies are retrospective or observational, and the few RCTs available may be subject to confounding.

* Risk factors for nephrotoxicity include concomitant use of aminoglycosides or piperacillin/tazobactam, rates at or above 4g per day, duration of therapy, and critical illness, among others.

* Vancomycin peaks do NOT correlate with toxicity or efficacy. Instead, this depends on the AUC/MIC ratio.

* The AUC (area under the curve) represents the amount of drug the bacteria see over a 24 hour period. The MIC (minimum inhibitory concentration) represents how resistant the bacteria are to that antibiotic.

* The AUC/MIC ratio is the best measurement of vancomycin’s effectiveness. The current rationale for checking vancomycin troughs is as a cheap, practical, but suboptimal surrogate marker for the AUC/MIC.



References:

(0:42 ) Levine DP. “Vancomycin: a history.” Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2006;42 Suppl 1:S5-12.

(3:08 ) Cheung RP, DiPiro JT. “Vancomycin: an update.” Pharmacotherapy 1986;6:15 3-69.

(4:59 ) Rybak MJ, Lomaestro BM, Rotschafer JC, et al. “Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.” Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2009;49:32 5-7.

(5:16 ) Sinha Ray A, Haikal A, Hammoud KA, Yu AS. “Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis.” Clinical journal of the American Society of Nephrology 2016;11:21 32-40.
Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Core IM: Mind the Gap on Vancomycin

Core IM: Mind the Gap on Vancomycin

Core IM Team